ACE2 and COVID-19: Specifically, some ACE2 activators, such as xanthenone (XNT) or diminazene aceturate (DIZE), have been proposed as having therapeutic potential for COVID-19 as it has been suggested that these drugs may reduce pulmonary fibrosis during SARS-CoV-2 infection [26,27].